Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through .
Vaccitech LimitedMarch 17, 2021 GMT
OXFORD, United Kingdom, March 17, 2021 (GLOBE NEWSWIRE) Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announces that it has raised $168 million in a Series B financing. This includes $43 million in convertible loan notes previously issued by Vaccitech that converted into Series B shares.
The Series B financing round was led by M&G Investment Management (part of M&G plc), with further participation from new investors including Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund, and Future Planet Capital among others. The Series B financing round was also support
Future Planet Capital: Future Planet Invests in Vaccitech s Series B Financing
Future Planet Capital has invested in a $168m Series B financing announced today by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation. As part of the Series B financing, $43 million in convertible loan notes previously issued by Vaccitech will convert into Series B shares, resulting in total gross proceeds to Vaccitech of $168 million before expenses.
Douglas Hansen-Luke, Executive Chairman of Future Planet Capital, explained: Our decision to support Vaccitech last year, before the results of the COVID-19 Vaccine AstraZeneca trials were known, has been vindicated by the vaccine s approval for emergency use by national and international regulators. The success of the COVID-19 Vaccine AstraZeneca has increased our confidence in Vaccitech s im
Link copied
By Jenny Strasburg A startup behind the Covid-19 vaccine developed by the University of Oxford and AstraZeneca PLC is planning an initial public offering that backers hope will be the biggest market debut of an Oxford spinoff in years. One hurdle: the university itself. Nine-hundred-year-old Oxford is wrestling with how to rewrite its rules for fostering companies created by its academics or born in its labs, while in a standoff with one that has been thrust into the spotlight by the pandemic. The startup, Vaccitech Ltd., has been pitching to potential investors and laying groundwork for a stock listing in New York as early as this year, according to people close to the plans and marketing documents reviewed by The Wall Street Journal.
Posted on 7556
Future Planet Capital has invested in a $168m Series B financing announced today by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation. As part of the Series B financing, $43 million in convertible loan notes previously issued by Vaccitech will convert into Series B shares, resulting in total gross proceeds to Vaccitech of $168 million before expenses.
Douglas Hansen-Luke, Executive Chairman of Future Planet Capital, explained:
“Our decision to support Vaccitech last year, before the results of the COVID-19 Vaccine AstraZeneca trials were known, has been vindicated by the vaccine’s approval for emergency use by national and international regulators. The success of the COVID-19 Vaccine AstraZeneca has increased our confidence in Vaccitech’
Provided by Dow Jones
By Jenny Strasburg LONDON The Oxford startup behind AstraZeneca PLC s Covid-19 vaccine has raised $168 million in new funding, which it plans to use to adopt its vaccine technology for the treatment of other diseases. The move is a step in Vaccitech Ltd. s preparations for going public as soon as this year, according to people familiar with the plans. The moves were first reported by The Wall Street Journal. The biotechnology company is raising funds at a time its vaccine work is in the spotlight. It played an early role developing a Covid-19 vaccine alongside scientists at the University of Oxford. AstraZeneca then teamed up with the university, promising to produce and distribute the shot globally. Vaccitech s co-founders are Oxford scientists leading the vaccine program.